Epstein-Barr virus (EBV) reactivation remains a life-threatening complication in recipients of a haploidentical haematopoietic stem cell transplantation (haploHSCT). Reconstitution of adaptive T lymphocytes is generally compromised at the early stages following transplant, suggesting an important role of other effector cells in preventing EBV infection. Our previous studies demonstrated that recovery of CD4 À CD8 À T cells negatively correlated with EBV reactivation after haploHSCT. In this prospective study on 132 adult patients with haematopoietic malignancy, recovery of T-cell subpopulations was characterized post-haploHSCT. We showed that the median counts of peripheral Vd2 cells were continuously lower in recipients with EBV reactivation compared with controls at 30, 60 and 90 days after haploHSCT (P values: 0Á006, <0Á001 and 0Á019, respectively). Landmark study further indicated that the cumulative incidence of EBV reactivation was significantly decreased in recipients with higher day-30 Vd2 counts. Activation of Vd2 cells upon EBV reactivation was accompanied by an induction of cell apoptosis. Cytotoxic effect of Vd2 cells on EBV-infected cells was confirmed by in vitro experiments. Together, our findings uncovered a significant correlation of recovered Vd2 with EBV reactivation following haploHSCT. These results will help to better understand the intrinsic anti-virus immunity and develop cd T-based therapy strategies after haematopoietic transplantation.
Although the outcome of patients who undergo haploidentical haematopoietic stem cell transplantation (haploHSCT) has significantly improved during the last decade (Worth et al, 2011; Wang et al, 2014; Kasamon et al, 2015; Chang et al, 2016) , life-threatening viral infection remains a challenging problem for further improving the overall survival. Epstein-Barr virus (EBV) reactivation and its related diseases, such as post-transplantation lymphoproliferative disorder (PTLD), are frequent complications with high mortality after haploHSCT (Cohen et al, 2005; Majhail, 2011; Xu et al, 2015) . It has been reported that functional recovery of the immune system was important for preventing opportunistic viral infections post-HSCT (Seggewiss & Einsele, 2010; Forcina et al, 2013) . Given that EBV reactivation usually occurs within the first 3 months after haploHSCT and EBV-specific adaptive CD8 + T cells are hardly detectable by that time (Meij et al, 2003; Heslop et al, 2010) , recovery of other effector T lymphocytes could be critical to the anti-EBV effect in this context. Our previous studies have demonstrated that the recovery of CD4 À CD8 À T cells was significantly hampered in haploHSCT recipients with EBV-DNAaemia Bian et al, 2017) . These results strongly imply that CD4 À CD8 À T cells play a role in anti-EBV activities following transplant. Notably, CD4 À CD8 À T cells are significantly heterogeneous and several subsets have been identified based on the expression of ab or cd T-cell receptors (TCR), or Natural killer cell markers (D'Acquisto & Crompton, 2011) .
In the peripheral blood of healthy donors, the majority (81%, 55%-92%, unpublished data) of CD4 À CD8 À T cells express TCRcd and cd T cells mainly comprise a dominant Vd2 + subpopulation and a minor Vd1 + subset (Zheng et al, (Xiang et al, 2014) , the anti-EBV role of reconstituted cd T cells and their subsets in the setting of treatment-induced severe immunodeficiency is elusive. Specifically, the recovery characteristics of Vd2 + T cells and their association with the occurrence of EBV reactivation after allogeneic HSCT remains unknown. By contrast, expansion of Vd2-negative cd T cells in response to EBV reactivation was reported in an individual patient following cord blood transplantation (Farnault et al, 2013) . Another study suggested that restriction of Vd1 + T lymphocytes in recipients of allogeneic HSCT might have a protective role in anti-EBV infection (Fujishima et al, 2007) . The recovery characteristics of Vd2 + T cells was not mentioned in both of the above reports. Thus, discrimination of which cd T-cell subset exactly correlated with EBV reactivation is a critical issue for the control of virus-associated complications in the context of haematopoietic transplantation. We conducted a prospective large cohort study on patients with haematopoietic malignancy and specifically focused on the recovery characteristics of cd T cells and their subpopulations upon EBV reactivation post-haploHSCT.
Patients and methods

Study design and patients
This prospective longitudinal study was conducted on patients who underwent haploHSCT and aimed to evaluate the correlation of reconstituted cd T-cell subpopulations with EBV reactivation. The inclusion criteria was as follows: (i) diagnosed as haematopoietic malignancy; (ii) aged 18-59 years; (iii) achieved complete remission before transplantation; (iv) received anti-thymocyte globulin (ATG) 10 mg/ kg as part of the conditioning regimen. Accordingly, a total of 132 consecutive haploHSCT recipients were included from February 2016 to August 2016 at Peking University People's Hospital. The study protocol has been approved by the Ethics Committee of Peking University People's Hospital. All recipients and their donors have signed consent forms.
The conditioning regimen including busulfan, cyclophosphamide and rabbit ATG (Imtix Sangstat, Lyon, France), and transplant procedures, graft-versus-host disease (GVHD) prophylaxis (ciclosporin A and short-term methotrexate with mycophenolate mofetil) and treatment were described previously (Wang et al, 2014; Chang et al, 2016) .
Diagnosis of viral and bacterial infection
Real-time quantitative polymerase chain reaction (qPCR) was performed to detect the viral-DNA loads in the peripheral blood. All recipients and donors were tested negative for EBV DNA before transplantation, and recipients were monitored weekly until day 100 after transplantation. Patients with an EBV-DNA load >1000 copies/ml in the peripheral blood on 2 or more consecutive occasions were diagnosed as EBV reactivation (EBV+, n = 22). The EBVÀ cohort (n = 110) generally represented patients whose EBV DNA load was undetectable (<500 copies/ml), a few patients who occasionally had a low level of EBV-DNA load (<1000 copies/ml) were also included in this cohort. EBV+ patients were treated with rituximab (monoclonal anti-CD20 antibody, 375 mg/m 2 weekly) until clearance of EBV-DNAaemia was achieved. Cytomegalovirus (CMV) DNA in the peripheral blood of recipients was routinely monitored similarly to EBV DNA, as described above. Bacteraemia was screened by blood culture test, Gram stain and acid-fast bacilli stain for patients who suffered a fever after transplantation.
Immunophenotyping analysis
Immunophenotyping for T lymphocytes was performed with flow cytometry at days 30, 60 and 90 post-haploHSCT. Briefly, fresh peripheral blood cells were stained with the following fluorochrome-labelled antibodies: anti-human CD3 (Catalogue number 300420), anti-human TCRcd (331218) and anti-human TCRVd2 (331406) were purchased from BioLegend (San Diego, CA, USA); anti-human CD4 (557871) and anti-human CD8 (347314) were bought from Becton Dickinson Sciences (BD, San Jose, CA, USA); anti-human TCRVd1 (130-100-519) were from Miltenyi Biotec (Bergisch Gladbach, Germany).
For activation assay of recovered cd T-cell subsets, fresh peripheral blood cells from haploHSCT recipients with or without EBV-DNAaemia were stained with anti-CD3, anti TCRVd2, anti TCRVd1 and anti-CD38 (BD, 555462) and anti-HLA-DR (BioLegend, 307606) antibodies.
For cell proliferation and apoptosis assay, cryopreserved peripheral blood mononuclear cells (PBMCs) isolated from haploHSCT recipients with or without EBV-DNAaemia were thawed and stained with cell surface markers as described above. Then cells were washed and resuspended in 100 ll of AnnexinV Binding Buffer (BioLegend) with 5 lg/ml of pycoerythrin (PE)-conjugated AnnexinV (BioLegend). To detect the expression of intracellular Ki67, cells were fixed and permeabilized with the Cytofix/Cytoperm kit (eBioscience, San Diego, CA, USA) according to the manufacturer's instructions, and stained with PE-ki67 antibody (BD). Polychromatic flow cytometric analyses were performed on a BD LSRFortessa TM Cell Analyser and further analysed using BD FACSDiva TM software.
Expansion of Vd2 + T cells and cytotoxicity assay in vitro
Peripheral blood mononuclear cells were isolated from healthy donors using standard Ficoll-Hypaque density were stimulated with the EBV-transformed B-lymphoblastoid cell line (EBV-LCL) at 1:1 ratio. After 6 h of co-culture, cells were stained with anti-TCRVd2, anti-CD38 and anti-CD19 antibodies, and 7-aminoactinomycin D (7-AAD) Viability Staining Solution (BD). Then the cells were analysed by flow cytometry. Interferon (IFN) concentration was measured as previously described (Jiang et al, 2005) . Briefly, an IFN-sensitive luciferase vector containing IFN-stimulated response element (ISRE) was constructed and stably transfected into HT1080 cells. HT1080-ISRE cells were seeded to 96-well plates and incubated with supernatants from co-culture of Vd2 + T cells and EBV-LCLs at different time courses, respectively. Cells were lysed 4 h later and measured by a Luciferase Reporter Assay System (Promega, Madison, WI, USA).
Statistical analysis
Statistical differences in age and cell counts of T-cell subpopulations at different time points between the groups were analysed using the Mann-Whitney U test. Differences between the groups in gender, type of primary disease, EBV serology, number of human leucocyte antigen (HLA) mismatches, and incidences of acute GVHD and infections, were analysed using the Chi-squared test. A time-dependent landmark study was performed to evaluate the correlation of cd T-cell recovery with the cumulative incidence of EBV reactivation after haploHSCT. Statistical significance was defined as P ≤ 0Á05, based on a two-tailed test. All calculations were performed using SPSS 22.0 statistical software (SPSS Inc, Chicago, IL, USA).
Results
Characteristics of patients
The clinical characteristics of haploHSCT recipients in EBV+ and EBVÀ groups are summarized in Table I (Table I ). All included patients underwent haploHSCT with a HLA-mismatched related donor and the proportions of different numbers of HLA mismatch were not significantly different between the EBV+ and EBVÀ groups (P = 0Á568). Procedures of donor priming (recombinant human granulocyte-colony stimulating factor), graft harvesting (peripheral blood progenitor cells and unmanipulated bone marrow), conditioning, and GVHD prophylaxis (as described in Methods) were all the same. These results minimized the possible influences of other factors on the recovery of T lymphocytes.
The incidences of other infections and acute GVHD were comparable between the recipients with and without EBV reactivation
To evaluate whether the recovery of cd T cells is specifically associated with EBV reactivation in the setting of haploHSCT, the occurrence of other infections attributed to CMV, bacteria or fungi was also compared. The incidences of CMV reactivation, bacteraemia and invasive fungal infection (IFI) were not significantly different between the EBV+ and EBVÀ groups (P > 0Á2, respectively; Table II ). Previous studies reported that development of acute GVHD (aGVHD) was associated with the reconstitution of T lymphocytes after allogeneic HSCT (Seggewiss & Einsele, 2010; Bosch et al, 2012 ). In the current study, incidences of II-IV and III-IV aGVHD were comparable between the EBV+ and EBVÀ groups (P = 0Á865 and P = 0Á417, respectively, Table II ). The onset time of aGVHD was also similar between the two groups (P = 0Á221).
Hampered recovery of Vd2 + T subset was correlated with the occurrence of EBV reactivation after haploHSCT (Table III) . Recovery of cd T cells was also delayed in EBV+ group on day 60, with P = 0Á046 in relative to the EBVÀ group. Notably, the median counts of Vd2 + T cells were continuously lower in the EBV+ group at 30, 60 and 90 days after haploHSCT (P value was 0Á006, <0Á001, and 0Á019, respectively, Table III) .
A time-dependent landmark study was performed to further validate the causal relationship of T-subpopulation recoveries with the occurrence of EBV reactivation after haploHSCT. All included patients were divided into lower-and higher-counts groups, respectively, based on the median numbers of CD4 + , CD4 
. A similar trend was observed when comparing the groups with lower and higher day-60 Vd2 + T-cell counts (P = 0Á078, Fig 1B) . Given the fact that the median onset time of EBV reactivation in this study was 51 days (38-82 days) after haploHSCT, these results implied that the rapidly recovered Vd2 + T cells could play a protective role against EBV reactivation in recipients.
Vd2/Vd1 ratio was significantly reversed after haploHSCT, which was even worse in recipients with EBV reactivation
In the peripheral blood of healthy donors, 69% (19-92%) and 16% (2-64%) of cd T cells were Vd2 + and of Vd1 + cells, (Fig 2A) . Interestingly, the proportions of Vd2 + cd T cells were continuously decreased in recipients from 30 to 90 days after haploHSCT in both EBVÀ (from 57% to 19%) and EBV+ (from 37% to 11%) groups, accompanying a skewed increase in the percentages of Vd1 + cd T cells, respectively (Fig 2B, D) . Vd2/Vd1 ratio was significantly reversed in the EBVÀ cohort at 60 and 90 days post-transplantation (0Á4) compared with the ratio (3Á2) in healthy donors (P < 0Á001), which was even lower at the same time points in the EBV+ cohort (0Á1 and 0Á2, respectively, Fig 2E) .
Significant activation and apoptosis of recovered Vd2 + rather than Vd1 + cd T cells were induced upon EBV reactivation after haploHSCT T cells were significantly induced by 43% (13-57%) and 33% (12-46%) in EBV+ group, respectively (P < 0Á001, respectively, Fig 3A, B) . By contrast, there was no statistical difference in the expression levels of CD38 ( Fig 3A) and HLA-DR (Fig 3B) in Vd1 + cd T cells between the EBV+ and EBVÀ groups, although Vd1 + cd T cells tended to be activated in both groups. These results demonstrated that recovered Vd2 + cd T cells were specifically sensitive to EBV reactivation after haploHSCT. Notably, the expression levels of Ki67 in both Vd2 and Vd1 cells were not statistically different between the patients with and without EBV reactivation, respectively (Fig 3C) . However, the percentage of Vd2 cells expressing AnnexinV was significantly increased in the EBV+ group compared with the control (P = 0Á002, Fig 3D) . By contrast, the proportions of AnnexinV-positive Vd1 cells were not significantly different irrespective of the EBV-reactivation status (Fig 3D) . These results demonstrated that EBV reactivation induced cell apoptosis of recovered Vd2 whereas proliferation of both subsets was not significantly changed.
In-vitro expanded Vd2 + T cells were activated by EBV-LCL and exerted cytotoxic effect
To further confirm the effect of Vd2 + T cells on EBV reactivation, peripheral Vd2 + T cells from healthy donors following expansion and purification in vitro were stimulated with EBV-LCL. As expected, IFN secretion by Vd2 + T cells was increased after a time-course co-culture with EBV-LCL (P < 0Á001, Fig 4A) . Consistently, the expression of CD38 (representing activation of cells) in Vd2 + T cells was significantly increased by 33-fold in response to EBV-LCL stimulation (Fig 4B, C) . Meanwhile, more 7-AAD positive 
EBV, Epstein-Barr virus.
*Cell recoveries are indicated by the 50th (25th, 75th) percentiles of the absolute counts. Significant P values are indicated in bold.
Fig 1.
Recovery of Vd2 + T cells inversely correlated with the cumulative incidence of EBV reactivation after haploHSCT. Time-dependent landmark study was conducted for the correlation of day-30 (A) and day-60 (B) Vd2 + T-cell counts with the cumulative incidence of Epstein-Barr virus (EBV) reactivation following haploidentical haematopoietic stem cell transplantation. (representing dead cells) EBV-LCLs (8Á6%) were found after co-culture with Vd2 + T cells compared with that (2Á4%) in control group (P < 0Á001, Fig 4D, E) . Taken together, these results indicated that Vd2 + T cells could effectively kill the EBV-infected cells.
Discussion
Opportunistic viral infections are the common complications in immune-compromised HSCT recipients leading to a high morbidity and mortality of virus-associated diseases. In terms of the intrinsic anti-EBV immunity, previous studies overwhelmingly focused on the virus-specific adaptive CD8 + T cells. However, the recovery of traditional adaptive immune cells was generally delayed and hardly detectable at the early stages after haploHSCT. In addition, ineffective prediction for post-transplant lymphoproliferative disorder by day 28 EBV-specific T-lymphocyte counts has been reported after allogeneic HSCT (Hoegh-Petersen et al, 2011) . Therefore, elucidating the EBV-associated reconstitution characteristics of other effector T cells is basically important for the prophylaxis and treatment of virus-associated complications. Following the findings from our retrospective studies that showed the negative relationship between CD4 À D8 À T-cell recovery and EBV activity Bian et al, 2017) , the current prospective study highlighted a significant correlation of a cd T-subset recovery with the occurrence of EBV reactivation after haploHSCT. It has been proposed that the exact roles of cd T-cell subpopulations during infections are dependent on their distinct functions and on the specific pathogens. With respect to the post-HSCT infections, Perko et al (2015) demonstrated that the reconstitution of cd T cells was associated with fewer Infections following allogeneic HSCT for paediatric leukaemia. However, this association tended to be significant in bacterial but not viral infections. So far, an active role of cd T cells in the immune response against CMV has been extensively investigated in the context of HSCT. Increasing evidence demonstrated that CMV reactivation could induce the expansion of Vd1 + or Vd2-negative cd T cells after allogeneic HSCT (Knight et al, 2010; Prinz et al, 2013; Scheper et al, 2013; Airoldi et al, 2015) . In contrast, studies on the association of cd T-cell recovery with EBV reactivation after HSCT are strikingly scarce. To date, a few studies have implicated that the reconstituted Vd1 + or Vd2-negative cd T cells might play a role in response to EBV infection in the setting of HSCT (Fujishima et al, 2007; Farnault et al, 2013) . However, no evidence referred to the recovered Vd2 + T cells in this regard.
Whether Vd2 + T cells exert anti-EBV activity in the real world, particularly in the immunocompromised context of allogeneic HSCT, is a critical issue and needs to be clearly investigated. Herein, we conducted a prospective longitudinal study on a large cohort and clarified an inverse correlation between the recovery levels of Vd2 + rather than Vd1 + T cells and the occurrence of EBV reactivation after haploHSCT. We believe that the recovered Vd2 cells were derived from donors because full donor chimerism was detected and confirmed in the peripheral lymphocytes of all included patients at 30 days after transplantation using DNA fingerprinting analysis of short tandem repeats. Since all recipients were transplanted with grafts combined with G-CSF-primed peripheral blood and bone marrow products, recovered cd T cells in recipients may contain both donor's mature Vd2 cells and those generated de novo from the donor's stem cells. This issue needs to be further investigated in future studies.
Recently, Ravens et al (2017) could be attributed to the high incidence (121/132, 92%) of CMV reactivation in the current study, which is in line with the findings from the literature that showed a CMV-stimulated expansion of Vd1 + T cells (Prinz et al, 2013; Airoldi et al, 2015) . Other reasons for the hampered recovery of Vd2 + T cells await further investigation.
Another interesting concern is whether the findings from this study could be observed in other HSCT settings. Our unpublished data showed that the median counts of recovered Vd2 cells after HLA-identical sibling HSCT were significantly higher than the Vd2 levels after haploHSCT. Of 30 included recipients with a HLA-matched sibling donor, none was positive for EBV-DNA load within 100 days after transplantation. These findings may suggest a potential role of Vd2 cells against EBV reactivation. As the transplant approach developed by our institute (also called "Beijing protocol") includes G-CSF priming of the haploidentical donor, ATG-based conditioning regimens and intensive postgrafting immunosuppression (ciclosporin A, mycophenolate mofetil and short-course methotrexate), data regarding haploHSCT with other strategies (e.g. high-dose post-transplant cyclophosphamide) was not available to us. We hope that our present study broaches this subject and more related investigations in other HSCT settings will be inspired.
Taken together, the current study highlighted an inverse correlation of the recovery of a special T-cell subset, Vd2 + T cells, with EBV reactivation following haploHSCT. Furthermore, we showed that recovered Vd2 + T cells were specifically activated and tended to be apoptotic upon EBV reactivation. In vitro expanded Vd2 + T cells were capable of exerting a cytotoxic effect on the EBV-infected B cells.
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Alongside the recognized association between Vd1 T-cell recovery and CMV reactivation, our findings could help a comprehensive understanding of the reconstitution characteristics of cd T cells and the pathogen-specific anti-virus immunity in the context of haematopoietic transplantation. Vd2 + T-cell-based strategies may improve the efficacy of prophylaxis and treatment against EBV reactivation, and the overall survival of haploHSCT recipients.
